Faculty profile

Geoffrey Liu

Back to faculty

ProfessorEpidemiology DivisionUniversity of Toronto

Geoffrey Liu

Professor

Epidemiology Division

Dalla Lana School of Public Health

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
203 publications in the last five years, latest in 2026.
Senior (last) author on 27 recent papers, a sign of leading a research group.
Principal investigator on 4 research grants (4 CIHR), most recently in 2020.
Supervisor on 4 trainee awards (4 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

400

Publications

1,142

Citations

174

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Anaplastic Lymphoma Kinase Rearrangements Drug Resistance Mechanisms Drug Sensitivity Screening Epidermal Growth Factor Receptor Epigenetics Genomics Non-Small Cell Lung Cancer Patient-Derived Organoids

Latest papers

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors
Journal of the National Cancer Institute · 2026 · senior author
Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts
Lung Cancer · 2026
Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison.
Lung cancer (Amsterdam, Netherlands) · 2026

All 400 publications

Latest funding

Liquid-biopsy profiling of EZH2-driven H3K27me3 remodeling to overcome treatment resistance in small-cell lung cancer
CIHR · 2026 · Co-investigator
$1,109,250
The N6-methyladenosine Epitranscriptome and Functional Landscape of Lung Adenocarcinoma
CIHR · 2025 · Co-investigator
$1,147,500
Improving Access and Wellbeing of Patients with Lung Cancer: A Randomized Controlled Trial of a Lay Navigation Program
CIHR · 2025 · Co-investigator
$753,526

All 20 grants and awards

From the 150 most recent of 400 publications.

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors

Melosky B, Juergens RA, Chu QSC, Cheema P, Snow S, Leighl NB, Blais N, Ionescu DN, McLeod D, Tsao M-S

Journal of the National Cancer Institute20265 citationsSenior author

DOI: 10.1093/jnci/djag008

Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts

Ko JJ, Blais N, Brade A, Clelland C, Juergens R, Liu G, Navani V, Snow S, Wheatley-Price P, Melosky B

Lung Cancer2026

DOI: 10.1016/j.lungcan.2026.109455

Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison.

Nagasaka M, Liu G, Pérol M, Chen W, Bazhenova L, Zhou C

Lung cancer (Amsterdam, Netherlands)2026

DOI: 10.1016/j.lungcan.2026.109538 PMID: 42531851

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.

Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT

Lung cancer (Amsterdam, Netherlands)2026First author

DOI: 10.1016/j.lungcan.2025.108858 PMID: 41500084

Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.

Zhang T, Zhao W, Wirth C, Díaz-Gay M, Yin J, Cecati M, Marchegiani F, Hoang PH, Leduc C, Baine MK, Travis WD, Sholl LM, Joubert P, Sang J, McElderry JP, Antony M, Klein A, Khandekar A, Hartman C, Rosenbaum J, Colón-Matos FJ, Miraftab M, Saha M, Lee OW, Jones KM, Caporaso NE, Wong MP, Leung KC, Hsiung CA, Chen CY, Edell ES, Santamaría JM, Schabath MB, Yendamuri SS, Manczuk M, Lissowska J, Świątkowska B, Mukeria A, Shangina O, Zaridze D, Holcatova I, Mates D, Milosavljevic S, Savic M, Bossé Y, Rothberg BEG, Christiani DC, Gaborieau V, Brennan P, Liu G, Hofman P, Homer R, Yang SR, Pesatori AC, Consonni D, Yang L, Zhu B, Shi J, Brown K, Rothman N, Chanock SJ, Alexandrov LB, Choi J, Cardelli M, Lan Q, Nowak MA, Wedge DC, Landi MT

Nature2026

DOI: 10.1038/s41586-025-09825-y PMID: 41372401

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies.

Cheema PK, Perdrizet KA, Sangha RS, Breadner D, Daaboul N, Farley S, Jao K, Liu G, Logan B, Melosky B, Reiman A, Snow S, Yadav S, Kassam S

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33020084 PMID: 41744848

Clinical Factors and Income Status are Associated with Depression and Anxiety in Head and Neck Cancer Patients.

Jethwa AR, Douglas CM, Hueniken K, Liu G, Bayley A, Huang SH, Hansen A, Chepeha D, Sarkis LM, Goldstein DP, Li M, Lajud SA, Almeida JR

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2026

DOI: 10.1177/19160216251398771 PMID: 41854105

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.

Munarriz BJ, Khan S, Hueniken K, Tam S, Patel D, Zhan L, Brown C, Eng L, Sacher A, Bradbury P, Leighl N, Liu G, Shepherd FA

JTO clinical and research reports2026

DOI: 10.1016/j.jtocrr.2025.100918 PMID: 41479841

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.

Penny L, Stutheit-Zhao EY, Michels BE, Rosing F, Zhao Z, Zheng Y, Zou J, Huang SH, Carlton J, McPartlin A, de Almeida JR, Goldstein D, Hope A, Hosni A, Kim J, Liu FF, Tsai CJ, Waldron JN, Spreafico A, Sanz-Garcia E, Siu LL, Waterboer T, Liu G, Bratman SV

International journal of cancer2026

DOI: 10.1002/ijc.70619 PMID: 42380047

Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

Lung cancer (Amsterdam, Netherlands)2026

DOI: 10.1016/j.lungcan.2025.108875 PMID: 41407631

Profile data last refreshed on July 30, 2025 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Geoffrey Liu

Research

Latest papers

Latest funding

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors

Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts

Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-na&#xef;ve ROS1+&#xa0;non-small cell lung cancer: A matching-adjusted indirect comparison.

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.

Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies.

Clinical Factors and Income Status are Associated with Depression and Anxiety in Head and Neck Cancer Patients.

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in&#xa0;Oropharyngeal Cancer.

Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].

Frequent collaborators

Wei Xu

Ming-Sound Tsao

Stephen Lam

Lawson Eng

Adrian Sacher

Doris Howell

Andrew Hope

Anna Spreafico

Paul Wheatley-Price

Osvaldo Espin Garcia

Philippe Joubert

Kazuhiro Yasufuku

Rosalyn Juergens

Meredith Giuliani

Peter Selby

Tracy Stockley

Nicole Mittmann

John Goffin

Nadeem Moghal

Elena Elimova

Ma'en Obeidat

Rayjean Hung

Serge Puksa

Paul Moayyedi

Gregory Pond

William Evans

Scott Tsai

Colm Boylan

Jean-claude Cutz

Som Mukherjee

Lori Stewart

Raimond Wong

James Wright

Jane Turner

Christopher Longo

Karen Zhang

Aly Karsan

Murray Krahn

Laura Anderson

Michael Au

Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison.

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.